Daiichi Sankyo Reports First patient Dosing in P- I/II Trial of DS-1594 to Treat Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
Shots:
- MD Anderson will sponsor and lead P-I/II study to assess DS-1594 as monothx. and in combination regimens for patients with r/r AML and ALL
- The 1EPs of the P-I part of the study is to determine the maximum tolerated dose and RP2D of DS-1594 in ~54 patients with AML or ALL regardless of mutation status. The 2EPs include CR and CR with CRh
- The P-II part of the study will evaluate DS-1594 at the established dose in four expansion cohorts of patients with specific genetic markers. The study enrolled ~170 patients which will initially be conducted only at MD Anderson with global expansion planned for P-II
Ref: BusinessWire | Image: The Japan Times
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com